Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies
Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies have?
Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies has 46 citations in the OpenAlex counts ScholarIQ stores.
When was Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies published?
Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies has 2017 year in the ScholarIQ index.
What is the open-access status of Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies?
Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies has hybrid oa status in the ScholarIQ index.
What is the DOI of Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies?
The DOI for Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies is on the source record.
What is the PMID of Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies?
The PMID for Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies is on the source record.
What is the OpenAlex record for Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies?
The OpenAlex for Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies is on the source record.